Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies Across Diverse Clinical Landscapes: An International Prospective Study
Ailawadhi S, Biru Y, Clavreul S, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤
The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource use in the United States and Western Europe
Annunziata K, Sternbach N, Tanaka H, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤
An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
Costa LJ, LeBlanc TW, Tesch H, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma
Gilbert O, Aiello J, Omel J, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤
The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study
Mohty M, Bahlis NJ, Nooka AK, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multisite Observational Study – Interim Results
Charalampous C, Kumar SK, Parrondo R, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤
Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Mol I, Hu Y, LeBlanc TW, et al
ASH 2024
- 美国血液学会年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
